Symptomatic Benefit of SESAME According to Phenotype
- PMID: 39445420
- PMCID: PMC11576234
- DOI: 10.1161/CIRCINTERVENTIONS.124.014440
Symptomatic Benefit of SESAME According to Phenotype
Keywords: aortic valve replacement; hypertrophic cardiomyopathy; left ventricular outflow tract obstruction; transcatheter mitral valve replacement; transcatheter myotomy.
Conflict of interest statement
Drs Ueyama, Inci, Lisko, Xie, Byku, Hanzel, Greenbaum, Babaliaros, and Gleason have received institutional research support from Abbott Vascular, Ancora Heart, Edwards Lifesciences, Gore Medical, JenaValve, Medtronic, Polares Medical, Transmural Systems, and 4C Medical. Dr Lederman is coinventors on patent applications, assigned to the National Institutes of Health, for transcatheter electrosurgical devices. Dr Byku has served as a consultant for Edwards Lifesciences and Shockwave Medical. Dr Hanzel has served as a consultant for Medtronic. Dr Greenbaum has served as a consultant to Abbott Vascular, Edwards Lifesciences, Excision Medical, and Medtronic; and has equity interests in Transmural Systems and Excision Medical. Dr Babaliaros has served as a consultant to Abbott Vascular, Edwards Lifesciences, and Medtronic; and has equity interest in Transmural Systems.
Figures
References
Grants and funding
LinkOut - more resources
Full Text Sources
